New shocking findings from a study involving the comparisons of the bivalent BNT162b2mRNA jabs and original monovalent boosters by researchers from University Hospital Wuerzburg – Germany and University of Oxford – UK is causing a stir among the research and medical communities.
The study involving healthcare workers has found that those receiving the new bivalent jabs had more adverse effects and were unable to work compared to those who received the monovalent boosters.
The study findings were published on a preprint server and are currently being peer reviewed.
Individuals receiving a second COVID-19 booster vaccination with the bivalent BNT162b2mRNA original/Omicron BA.4-5 vaccine reported adverse reactions more frequently compared to those receiving the monovalent vaccine.
Also, there was a trend towards an increased rate of inability to work and intake of PRN medication following bivalent vaccination.
Limitations of this study are the retrospective questionnaire-based assessment, the lack of randomization and blinding as well as the difference in the interval between both booster vaccinations between the two groups.
Our study focused on a direct comparison between the monovalent BNT162b2mRNA and the corresponding bivalent vaccine.
In the light of preprints reporting inconclusive results in neutralizing antibody levels between the compared vaccines,[5-7] our results and further studies on safety and reactogenicity of bivalent COVID-19 booster vaccines are highly important to aid clinical decision making in the choice between bivalent and monovalent vaccinations.